Daria Mochly-rosen PhD

Dr. Daria Mochly-Rosen is a Professor of Chemical and Systems Biology and the George D. Smith Professor for Translational Medicine at Stanford University School of Medicine. She leads a multi-disciplinary research lab that includes chemists, biochemists, biologists and physician scientists and has used her basic research discoveries to develop several drugs leads for human diseases with interest in mitochondrial biology and pathology. She has published over 230 papers and over 30 patents and patent applications and have founded three companies: KAI Pharmaceuticals (2003-2011), ALDEA (now Aviv Therapeutics; 2013-) and Mitoconix (2016-).

Dr. Mochly-Rosen is the founder and co-director of SPARK (SPARKmed.stanford.edu), a university-wide program focusing on translational research to benefit patients and society. Now in its 10th year, SPARK helped about 73 inventors (60% of the participants of the program) of biopharmaceuticals and diagnostics bring their invention to clinical studies and/or to licensing. This unique program provides education in drug discovery and development and supports the school’s mission in translational research. SPARK programs have now been established or are under development in two dozen academic institutions in the US and throughout the world, increasing the likelihood that new treatments will be developed from academic research efforts across the globe.